| Item Type | Name |
|
Academic Article
|
Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy.
|
|
Academic Article
|
Male breast cancer during treatment with leuprolide for prostate cancer.
|
|
Academic Article
|
Men's knowledge and beliefs about prostate cancer: education, race, and screening status.
|
|
Academic Article
|
The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function.
|
|
Academic Article
|
Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?
|
|
Academic Article
|
A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.
|
|
Academic Article
|
Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone.
|
|
Concept
|
Prostate
|
|
Concept
|
Prostate-Specific Antigen
|
|
Academic Article
|
DNA damage levels in prostate cancer cases and controls.
|
|
Academic Article
|
A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry.
|
|
Academic Article
|
Racial and Socioeconomic Disparities in MRI-Fusion Biopsy Utilization to Assess for Prostate Cancer.
|
|
Academic Article
|
Racial Disparities in Prostate Specific Antigen Screening and Referral to Urology in a Large, Integrated Health Care System: A Retrospective Cohort Study.
|
|
Academic Article
|
Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells In Vitro.
|
|
Academic Article
|
Epidemiology and survival outcome of adult kidney, bladder, and prostate rhabdomyosarcoma: A SEER database analysis.
|
|
Academic Article
|
Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.
|
|
Academic Article
|
A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry.
|
|
Academic Article
|
MAGI2 is an independent predictor of biochemical recurrence in prostate cancer.
|
|
Academic Article
|
Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry.
|
|
Academic Article
|
MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma: ?A Comparison With AMACR.
|
|
Academic Article
|
NF-?B and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.
|
|
Academic Article
|
Does Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms.
|
|
Academic Article
|
MAGI-2 in prostate cancer: an immunohistochemical study.
|
|
Academic Article
|
NF-?B and androgen receptor variant expression correlate with human BPH progression.
|
|
Academic Article
|
Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia.
|
|
Academic Article
|
Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer.
|
|
Academic Article
|
NF-?B gene signature predicts prostate cancer progression.
|
|
Academic Article
|
Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network.
|
|
Academic Article
|
Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume.
|
|
Academic Article
|
Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer.
|
|
Academic Article
|
PPAR?: a molecular link between systemic metabolic disease and benign prostate hyperplasia.
|
|
Academic Article
|
Serum methionine metabolites are risk factors for metastatic prostate cancer progression.
|
|
Academic Article
|
Smaller prostate size predicts high grade prostate cancer at final pathology.
|
|
Academic Article
|
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
|
|
Academic Article
|
Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival.
|
|
Academic Article
|
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
|
|
Academic Article
|
Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer.
|
|
Academic Article
|
Cytokine genetic polymorphisms and prostate cancer aggressiveness.
|
|
Academic Article
|
Intake of plant foods and associated nutrients in prostate cancer risk.
|
|
Academic Article
|
Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy.
|
|
Academic Article
|
Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy.
|
|
Academic Article
|
Interactions of cytokine gene polymorphisms in prostate cancer risk.
|
|
Academic Article
|
A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy.
|
|
Academic Article
|
Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?
|
|
Academic Article
|
Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
|
|
Academic Article
|
Complementary and alternative medicine for advanced prostate cancer.
|
|
Academic Article
|
Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer.
|
|
Academic Article
|
Prostate cancer and bone metastases: medical treatment.
|
|
Academic Article
|
The androgen receptor CAG repeat and prostate cancer risk.
|
|
Academic Article
|
Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
|
|
Academic Article
|
Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
|